Hydroquinone is a prescription skin lightener used for melasma, the brown patches that sun and hormones can leave on the face. Most of its trial evidence is for combinations rather than the cream alone, and the comparisons are small or older.
The triple combination
The largest trial in our search is a pair of 8-week, investigator-blind studies with 641 mostly female adults with melasma (Taylor et al., Cutis 2003). Each compared a triple cream of tretinoin 0.05%, hydroquinone 4% and fluocinolone 0.01% with dual combinations of the same ingredients. At week 8, 26.1% of the triple-cream group had complete clearing, against 4.6% in the dual-combination groups together.
Against kojic acid
A 2013 comparison of hydroquinone 4% with kojic acid 0.75% in facial melasma (Monteiro et al., Indian J Dermatol) found that hydroquinone responded earlier, by week 4, and was superior at the end of 12 weeks. It is a single comparison, and kojic acid's evidence base is thin across the board.
Against azelaic acid
The two comparisons point in different directions. In a 1989 double-blind study of 155 patients over 24 weeks, 73% on azelaic acid 20% had good to excellent results, against 19% on hydroquinone 2% (Verallo-Rowell et al.). A 2023 meta-analysis of six randomized trials with 673 people found that azelaic acid lowered the melasma severity score (MASI) more than hydroquinone, mean difference -1.23 (95% CI -2.05 to -0.40), with no difference in pigment reduction or adverse events (Albzea et al., Cureus 2023). The 2023 analysis pools trials of different strengths and durations.
What the reviews rate
A systematic review of 35 randomized trials of topical melasma treatments (Austin et al., J Drugs Dermatol 2019) gave strong recommendations to cysteamine, triple combination therapy and tranexamic acid. Hydroquinone alone was not in that top group. The authors note that triple combination agents are effective but carry a theoretical risk of ochronosis, a darkening of the skin with long-term use.
What this does not say
- Most trial strengths were 4% hydroquinone or 2%; the creams in our catalog are 6% and 8%, and we did not find trials of those strengths.
- The triple-cream trial ran eight weeks in Fitzpatrick types I to IV; it does not show what happens with longer use or in darker skin.
- Results from combination creams are not results for hydroquinone alone, and the reviews do not rank hydroquinone on its own.
How we use this
Our physicians decide whether a lightener fits your skin type, how long to use it and when to stop, using the triple-combination evidence as the reference point. We do not promise a time to fade from these trials.
Explore weight loss treatmentsSources
- 1.Taylor SC et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis 2003;72(1):67-72. Cutis
- 2.Monteiro RC et al. A comparative study of the efficacy of 4% hydroquinone vs 0.75% kojic acid cream in the treatment of facial melasma. Indian J Dermatol 2013;58(2):157. Indian Journal of Dermatology
- 3.Verallo-Rowell VM et al. Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma. Acta Derm Venereol Suppl 1989;143:58-61. Acta Dermato-Venereologica
- 4.Albzea W et al. Azelaic acid versus hydroquinone for managing patients with melasma: systematic review and meta-analysis of randomized controlled trials. Cureus 2023;15(7):e41796. Cureus
- 5.Austin E, Nguyen JK, Jagdeo J. Topical treatments for melasma: a systematic review of randomized controlled trials. J Drugs Dermatol 2019;18(11). Journal of Drugs in Dermatology